Belumosudil clinical trials
Also written KD025, REZUROCK and SLx-2119.
How each study uses belumosudil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the belumosudil studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Jul 2021 · REZUROCK · NDA 214783 (FDA, Drugs@FDA)
- European Union
- 24 Mar 2026 · Rezurock · EMEA/H/C/006421 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 5 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 13
Kadmon, a Sanofi Company (10) · Kadmon Corporation, LLC (8) · Sanofi (7) · M.D. Anderson Cancer Center (2) · BioNova Pharmaceuticals (Shanghai) LTD. (1) · The Methodist Hospital Research Institute (1) · Dennis Kim (1) · Stanford University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test belumosudil.
- Jan 2027Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsPhase 1 · Sanofi
- May 2027Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant RecipientsPhase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
- Jun 2027BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)Phase 2 · Dana-Farber Cancer Institute
- Aug 2027A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)Phase 4 · Sanofi
- Aug 2027Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple MyelomaPhase 1/2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses belumosudil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 39
- Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsNot yet recruitingPhase 1SanofiNCT07726914Written as Belumosudil
- A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)Not yet recruitingPhase 4SanofiNCT07135973Written as Belumosudil
- A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host DiseaseRecruitingPhase 3SanofiNCT07771439Written as Belumosudil
- A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft DysfunctionRecruitingPhase 3SanofiNCT06082037Written as Belumosudil
- Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)Not yet recruitingPhase 2Dennis KimNCT07643025Written as Belumosudil
- A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)RecruitingPhase 2SanofiNCT07116031Written as Belumosudil
- Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host DiseaseRecruitingPhase 2Fred Hutchinson Cancer CenterNCT05996627Written as Belumosudil
- Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHDRecruitingPhase 1M.D. Anderson Cancer CenterNCT07127926Written as Belumosudil
- IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHDNot yet recruitingPhase 1Stanford UniversityNCT07484113Written as Belumosudil
- Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant RecipientsRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06476132Written as Belumosudil
- Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06105554Written as Belumosudil mesylate
- A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell TransplantRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07006506Written as Belumosudil
- BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)RecruitingPhase 2Dana-Farber Cancer InstituteNCT05922761Written as Belumosudil
- Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney TransplantationEnrolling by invitationPhase 2The Methodist Hospital Research InstituteNCT06751602Written as Belumosudil 200 mg QD
- NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid TumorsRecruitingNot applicableCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06509490Written as KD-025 cell injection
- NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid TumorsRecruitingEarly Phase 1jianming xuNCT05382377Written as KD-025
- A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.Active, not recruitingPhase 3SanofiNCT06143891Written as Belumosudil
- Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-DiseaseSuspendedPhase 2Northside Hospital, Inc.NCT06046248Written as Belumosudil
- A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic TherapiesCompletedPhase 4SanofiNCT06616415Written as Belumosudil
- Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic TherapyWithdrawnPhase 2Kadmon, a Sanofi CompanyNCT05567406Written as Belumosudil
See all 39 studies that test belumosudil →
Given beside what is tested · 2 — belumosudil is usual care or a partner of the new treatment
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolRecruitingPhase 1/2SanofiNCT04643002Written as Belumosudil
- A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male SubjectsCompletedPhase 1Kadmon, a Sanofi CompanyNCT05806567Written as Belumosudil
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
Stopped1
- Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-DiseaseSuspendedOct 16, 2026NCT06046248
Codes
What other systems call belumosudil · ClinicalTrials.gg INT001666
- MeSH (NLM) C000718240belumosudilOne source ClinicalTrials.gov
- UNII (FDA) 834YJF89WOBELUMOSUDILConfirmed FDA, Wikidata
- RxNorm 2564025One source FDA
- Wikidata Q27269397belumosudilConfirmed FDA, Wikidata
- NCI Thesaurus C128786BelumosudilOne source FDA
- DrugBank DB16703One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718240 | belumosudil | One source ClinicalTrials.gov |
| UNII (FDA) | 834YJF89WO | BELUMOSUDIL | Confirmed FDA, Wikidata |
| RxNorm | 2564025 | — | One source FDA |
| Wikidata | Q27269397 | belumosudil | Confirmed FDA, Wikidata |
| NCI Thesaurus | C128786 | Belumosudil | One source FDA |
| DrugBank | DB16703 | — | One source Wikidata |
Also registered as belumosudil mesylate (UNII 6MX7XE1M0U · RxNorm 2565692).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.